Quest Diagnostics (NYSE:DGX) Price Target Raised to $260.00

Posted by Patrick Bannon on Sep 23rd, 2026

Quest Diagnostics (NYSE:DGX – Free Report) had its price target raised by Truist Financial from $250.00 to $260.00 in a research note released on Monday morning, MarketBeat reports. They currently have a hold rating on the medical research company’s stock.

Several other equities analysts also recently issued reports on DGX. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 price objective on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Weiss Ratings raised Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, August 12th. Barclays boosted their price target on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. JPMorgan Chase & Co. increased their price target on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average target price of $237.08.

Read Our Latest Research Report on DGX

Quest Diagnostics Trading Down 0.9%

Shares of NYSE:DGX opened at $232.71 on Monday. The company has a market cap of $25.69 billion, a PE ratio of 24.70, a P/E/G ratio of 2.14 and a beta of 0.55. The company’s 50-day moving average price is $235.21 and its 200 day moving average price is $211.29. Quest Diagnostics has a fifty-two week low of $171.18 and a fifty-two week high of $248.84. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $2.62 EPS. Quest Diagnostics’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Sell-side analysts anticipate that Quest Diagnostics will post 11.15 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.

Insider Buying and Selling

In other news, SVP Michael E. Prevoznik sold 22,677 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the completion of the transaction, the senior vice president owned 37,557 shares in the company, valued at approximately $9,130,482.27. This trade represents a 37.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the transaction, the senior vice president directly owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 34,277 shares of company stock valued at $8,316,493 over the last three months. Company insiders own 0.88% of the company’s stock.

Institutional Trading of Quest Diagnostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Concurrent Investment Advisors LLC raised its holdings in shares of Quest Diagnostics by 1.2% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock valued at $1,099,000 after purchasing an additional 62 shares during the period. PFG Private Wealth Management LLC grew its holdings in Quest Diagnostics by 5.1% during the second quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company’s stock worth $308,000 after purchasing an additional 71 shares during the period. Hantz Financial Services Inc. grew its holdings in Quest Diagnostics by 9.6% during the fourth quarter. Hantz Financial Services Inc. now owns 835 shares of the medical research company’s stock worth $145,000 after purchasing an additional 73 shares during the period. Koshinski Asset Management Inc. increased its position in Quest Diagnostics by 4.2% during the first quarter. Koshinski Asset Management Inc. now owns 2,062 shares of the medical research company’s stock worth $404,000 after buying an additional 84 shares during the last quarter. Finally, Wedmont Private Capital raised its stake in Quest Diagnostics by 2.8% in the second quarter. Wedmont Private Capital now owns 3,120 shares of the medical research company’s stock valued at $647,000 after buying an additional 86 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

Positive Sentiment: Quest’s diagnostic-testing growth, customer wins, advanced diagnostics and artificial-intelligence initiatives support a constructive long-term outlook. One analyst remains bullish despite Medicare-related risks. Quest Diagnostics: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Positive Sentiment: Truist Financial assigned Quest Diagnostics a $260 price target, implying analysts see additional upside from current levels. Quest Diagnostics Given New $260 Price Target at Truist Financial
Positive Sentiment: Zacks highlighted DGX as a potential long-term value stock, which may attract investors seeking defensive healthcare exposure at a reasonable valuation. Why Quest Diagnostics Is a Top Value Stock for the Long-Term
Positive Sentiment: A Quest study finding substantial co-exposure to multiple tick-borne diseases highlights broader testing needs and could support demand for specialized diagnostics. Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
Neutral Sentiment: Quest will report third-quarter 2026 results before the market opens on October 22. The announcement itself does not change fundamentals but sets the next major catalyst for earnings, guidance and reimbursement commentary. Quest Diagnostics to Release Third Quarter Financial Results
Neutral Sentiment: Recent comparisons characterize DGX as having outperformed the Nasdaq over the past year, while a GeneDx comparison offers context on competitive positioning rather than a new company-specific catalyst. Is Quest Diagnostics Stock Outperforming the Nasdaq?
Negative Sentiment: The key bearish catalyst is concern that the government believes Medicare has overpaid Quest and may reduce reimbursement rates next year. Investors fear the cuts could pressure revenue, margins and earnings, prompting the sharp decline in the stock. Why Quest Diagnostics Holdings Stock Dropped Today

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.

Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.